project . 2018 - 2020 . Closed

Tackling MDR Gram-negative infections by an MGB conjugation strategy

Wellcome Trust
  • Funder: Wellcome TrustProject code: 210103
  • Funded under: Immune System in Health and Disease Funder Contribution: 81,555 GBP
  • Status: Closed
  • Start Date
    01 Apr 2018
    End Date
    01 Jan 2020
Description
Urgent action is required to develop new and novel drugs to treat multi drug resistant bacterial infections. Without this, we risk slipping into a “post-antibiotic era” where a cut or simple operation are life-threatening events, such as they were before the discovery of penicillin. After a successful medicinal chemistry programme targeting Gram-positive bacteria, specifically successfully completing phase I clinical trials for a novel C. diff drug, MGB-BP-3, we are now primarily concerned with developing new antibiotics that are effective against the Gram-negative pathogens from the ESKAPE pathogen set, Escherichia coli, Klebsiella pneumoniae, Acinetobacter bau...
Description
Urgent action is required to develop new and novel drugs to treat multi drug resistant bacterial infections. Without this, we risk slipping into a “post-antibiotic era” where a cut or simple operation are life-threatening events, such as they were before the discovery of penicillin. After a successful medicinal chemistry programme targeting Gram-positive bacteria, specifically successfully completing phase I clinical trials for a novel C. diff drug, MGB-BP-3, we are now primarily concerned with developing new antibiotics that are effective against the Gram-negative pathogens from the ESKAPE pathogen set, Escherichia coli, Klebsiella pneumoniae, Acinetobacter bau...
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue